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Abstract
This paper presents a ten-year course of the disease in a patient with pancreatic neuroendocrine tumour NEN G1, and with confirmed 
single, asymptomatic metastasis to the left cardiac ventricle. Initially, the cardiac metastasis was visible only on a positron emission to-
mography (PET) scan using gallium-68-labelled somatostatin analogue; the sensitivity of an echocardiography scan was lower. Despite 
the advanced stage of the disease, surgical excision of the cardiac metastasis was performed. The patient underwent a total of eight opera-
tions, and received chemotherapy, radiotherapy and somatostatin analogues. Currently, he is on a targeted therapy with everolimus. As a 
result of the treatment, the patient remains in a good general condition. This is the second described case of cardiac metastasis of PNEN. 
Using different methods of treatment in the case of generalised pancreatic neuroendocrine tumour with low proliferative potential, patients 
are offered the chance to prolong their survival and maintain a good quality of life. (Endokrynol Pol 2014; 65 (3): 232–237)
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Streszczenie
W pracy przedstawiono 10-letni przebieg choroby u pacjenta z nowotworem neuroendokrynnym trzustki NEN G1, u którego stwierdzono 
pojedynczy, bezobjawowy przerzut do lewej komory serca. Przerzut do serca widoczny był początkowo jedynie w badaniu pozytronowej 
tomografii emisyjnej z użyciem analogu somatostatyny znakowanej galem-68 , czułość badania echokardiograficznego była mniejsza. 
Pomimo zaawansowanej choroby wykonano operacyjne usunięcie przerzutu z serca. W sumie chory był 8-krotnie operowany, otrzy-
mywał chemioterapię, radioterapię oraz analogii somatostatyny, a obecnie prowadzona jest terapia celowana everolimusem. W wyniku 
zastosowanego leczenia chory pozostaje w dobrym stanie ogólnym. Jest to drugi opisany przypadek z przerzutem PNEN do serca. 
Stosowanie różnych metod leczenia w przypadku uogólnionego nowotworu neuroendokrynnego trzustki o niskim potencjale prolifera-
cyjnym daje szansę na wydłużenie przeżycia przy zachowaniu dobrej jakości życia. (Endokrynol Pol 2014; 65 (3): 232–237)
Słowa kluczowe: nowotwór neuroendokrynny trzustki; analog somatostatyny; przerzut do serca 
Introduction
The frequency of diagnosing neuroendocrine neo-
plasms of the gastrointestinal system has been on the 
rise due to both an actual increase in the incidence of 
the disease and  advances in the diagnostics of these 
tumours. According to various sources, pancreatic 
neuroendocrine tumours (PNENs) constitute from 2% 
to 10% of all tumours affecting this organ [1–3]. The in-
cidence of PNENs is estimated to be 0.32/100,000/year 
[4]. PNENs are classified as being either functioning 
and non-functioning. The former constitute 10–30% of 
cases and are associated with symptoms of hormone 
excess. The latter constitute approximately 50–80% 
of cases and do not produce sufficient amounts of 
hormones and/or biogenic amines to produce clinical 
symptoms [5]. The implementation of the new WHO 
classification in 2010 modified the terminology of 
neuroendocrine tumours. The term “neuroendocrine 
tumours/neoplasm” (NET/NEN) refers to highly 
differentiated tumours, such as NEN G1 (Ki-67< 
or = 2%) and NEN G2 (Ki-67 3–20%). Moreover, one 
can distinguish neuroendocrine carcinoma NEC from 
mixed adenoneuroendocrine carcinoma MANEC 
[6, 7]. Radical surgical treatment is the only fully effec-
tive curative procedure [8]. The majority of patients 
are diagnosed at an unresectable or metastatic stage 
of the disease. Patients with low or intermediate 
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grade advanced disease have a median survival time 
of 24 months, while patients with poorly differentiated 
tumours have a median survival time of approximately 
ten months [9, 10].
In cases of advanced PNENs, various treatment 
methods are used, including cytoreductive surgeries, 
biotherapy with labelled somatostatin analogues, iso-
tope radiation therapy, chemotherapy and targeted 
medication [4, 8, 11–13]. Pancreatic neuroendocrine 
neoplasms primarily metastasise to the liver, lymph 
nodes and bones [5]. Metastases to mediastinal struc-
tures are infrequent. Cardiac metastases in PNENs 
are case-based reasoning. To date, one case has been 
published concerning a patient diagnosed with 
PNEN G2, with multiple synchronous metastases to 
the lymph nodes, bones and the heart found upon 
diagnosis [14]. 
This report describes the course of a ten-year treat-
ment of a patient with pancreatic NEN G1, diagnosed 
with metastasis to the left ventricle of the heart, who 
underwent successful operation. The ongoing follow-
up systemic treatment makes it possible to prolong the 
patient’s survival period. 
Case report
A 40-year-old man had been experiencing slight pain 
in the right epigastric region and dyspepsia for two 
years. An abdominal ultrasound revealed a tumour of 
30 mm in diameter in the head of the pancreas, and 
an abdominal CT scan showed abnormal image of the 
pancreas. The patient reported to the Oncology Centre 
in Gdańsk, where he stayed until October 2011.
In September 2003, an operation was performed 
(Operatio modo Whiple with excisio partialis vena cava 
inferior). Histopathological examination revealed Car-
cinoma neuroendocrinale G3 (WHO 2000), ceratine (+), 
focus chromogranin (+), synaptophizin (+), S-100 (+), 
peripancreatic lymph nodes with metastases, malignant 
infiltration of the lymph nodes exceeds bags and cov-
ers the surrounding adipose tissue. After two years, 
a tumour was confirmed in the abdominal wall. In 
March 2004, the patient was operated on (excisio tumour 
tegmentis abdominis). Histopathological examination 
showed no tumour cells. In September 2005, a posi-
tron emission tomography scan with fluorine-labelled 
glucose analogue (18FDG-PET/CT) was performed, 
revealing foci of an active malignancy process in the 
abdominal cavity in the form of changes in the aortic 
area (diameter: 19 and 16 mm, Standardized Uptake 
Value — SUV 18.1), a change close to the cavity of the 
right kidney (diameter: 30 mm — SUV 22.8), a change 
on the left side of the aorta (diameter: 19 mm — SUV 
16.4), a change around the right iliac vessels (diameter: 
17 mm — SUV 21.5), and a change at the L3 area on 
the left side of the aorta (diameter: 11 mm — SUV 
8.8). In October 2005, an exploratory laparotomy was 
performed and specimens were collected for histo-
pathological consultation, which revealed Carcinoma 
neuroendocrinale metastaticum. A positron emission to-
mography scan using gallium-68-labelled somatostatin 
analogues (68Ga-PET/CT ) revealed lack of somatostatin 
receptor expression, disseminated disease and no 
hormonal activity of the tumour. Further CT scans 
and 18FDG-PET/CT confirmed progression of the dis-
ease. The patient was qualified for chemotherapy and 
received six courses of streptozotocin plus 5-Fu from 
March to August 2006. Due to a new focus in the right 
ureter area with pressure on the ureter, the patient was 
re-operated on in 2006 — partial resection of the right 
ureter. A decision was then made to start somatostatin 
analogue therapy, which was continued until June 2007. 
In October 2008, a metastatic tumour was removed from 
the retroperitoneal space. From January to March 2009, 
the patient received radiation therapy at the site of the 
removed mid-abdomen recurrence (the total dose of 
54 Gy, in 30 fractions). Further 18FDG-PET/CT revealed 
recurrence in the retroperitoneal space; another sur-
gery to remove the recurrence was performed in Oc-
tober. In January 2010, a 18FDG-PET/CT scan revealed 
new foci of the disease: a change in the left ventricle 
(13 × 15 mm — SUV 11.3), a change in the liver (13x15 
mm), a change in the aortic region (10 × 15 mm — SUV 
8.6). The18FDG-PET/CT scan was repeated in November 
2010, revealing metabolic progression of the disease 
and the 68Ga-PET/CT scan showed that somatostatin 
receptors were present in the foci. Chromogarnin A 
was elevated at 588 ng mL (norm < 100). Echocardi-
ography, which was performed twice, did not confirm 
any pathology; in particular, the left ventricle showed 
no hypertrophy or sections of disturbed contractility, 
and had proper ejection fraction. The patient had prob-
lems with both flatulence and diarrhoea, but no weight 
loss occurred. A somatostatin analogue therapy was 
started. The 68Ga-PET/CT scan was repeated in April 
2011, revealing progression of the disease (a change 
around the intestinal loop — 16 mm, SUV 43.5 (Fig. 1); 
changes in the aortic region — 24 × 17 × 29 mm, SUV 
31.4 (Fig. 2); change in the left mediastinum — diameter: 
15 mm, SUV 32.1 (Fig. 3.) 
In November 2011, the patient was admitted to the 
Division of Endocrinology, Silesian Medical University 
in Katowice. The test results indicated elevated concen-
tration of chromogranin A — 26 U/L (norm 2–18), and 
after conducting a histopathological re- consultation 
of all the microscopic specimens, a final diagnosis was 
given, namely NEN G1 (WHO 2010), Ki-67 < 2%. Imag-
ing examinations were scheduled. 
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Change in the intestinal loop 
(diameter 16 mm —SUV 43.5)
Figure 1. Image of the 68Ga-PET/CT scan shows expression of somatostatin receptors in change in the intestinal loop
Rycina 1. Badanie 68Ga-PET/CT uwidaczniające ekspresję receptorów somatostatynowych  pomiędzy pętlami jelita cienkiego
Figure 2. Image of the 68Ga-PET/CT scan shows expression of somatostatin receptors in numerous changes of region of aorta 
Rycina 2. Badanie 68Ga-PET/CT uwidaczniające ekspresję receptorów somatostatynowych w licznych zmianach ogniskowych okolicy aorty
Numerous changes in the region of aorta
(24 × 17 × 29 mm — SUV 31.4)
Figure 3. Image of the 68Ga-PET/CT scan shows expression of somatostatin receptors in mediastinum focus (reproduced with permission 
of L. Królicki, Department of Nuclear Medicine, Medical University, Warsaw)
Rycina 3. Badanie 68Ga-PET/CT uwidaczniające ekspresję receptorów somatostatynowych w ognisku zlokalizowanym w śródpiersiu 
(opublikowane za pozwoleniem: L. Królicki, Zakład Medycyny Nuklearnej Akademii Medycznej w Warszawie)
Change in the mediastinum   
(diameter 15 mm — SUV 32.1)
In April 2012, the patient was re-operated on in 
the Centre in Gdańsk. An exploratory laparotomy 
was performed, finding an irremovable recurrence 
of the tumour in the small intestine mesentery. 
In July 2012, a 68Ga-PET/CT scan was performed, reveal-
ing changes in the aortic region (43 × 40 mm — SUV 
18.3) and a new change (25 × 24 mm — SUV 12.5); 
a change in the mediastinum (diameter: 15 mm — 
SUV 22.7), and disease progression was detected 
(Fig. 4). 
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In September 2012, echocardiography was re-
peated, revealing a focus on the apical side wall of 
the left ventricle measuring 24 mm in diameter. The 
patient was admitted to the Department of Cardiac 
and Vascular Surgery in Gdańsk for surgical treatment 
of a left ventricular tumour. In December 2012, the 
tumour from the left ventricle of the heart was excised, 
followed by Dacron patch implantation. Histopatho-
logical consultation indicated the following: metastasis 
neoplasm NEN G2 (Ki-67 4%); size 3 × 2.3 × 1.5 cm 
with immunohistochemical expression of synapto-
physin and CD56. In December 2012, a 68Ga-PET/CT 
scan was performed, revealing an active malignancy 
in the abdomen, the possibility of infiltration into the 
gastric wall as well as three foci in the aortic region 
— 40 × 33 × 37 mm — SUV 20.6, 37 ×34 × 28 mm 
— SUV 17.2, 36 × 25 × 43 mm — SUV 23.8 (Fig. 5).
Treatment with everolimus at a dose of 10 mg per 
day was commenced. In March 2013, an abdominal 
MRI showed a pathological structure (24 mm) in 
the site of the removed pancreas and a focus in 
the duodenojejunal region (37 mm). The follow-up 
68Ga-PET/CT scan, which was performed in June 
2013, revealed a regression in the size of the lesions, 
with overexpression of somatostatin receptors. Only 
two lesions were visible: a change in the head of 
the pancreas, measuring 20 × 25 × 20 mm, SUV 
20.9 and a change in the aortic region, measuring 
42 × 29 × 43 mm, SUV 17.5. In a follow-up MR imag-
ing examination in September 2013, the changes in 
the site after pancreas removal and in the projection 
of the duodenojejunal flexure looked the same. The 
patient continues treatment with everolimus and 
somatostatin analogue. The general condition of the 
patient is good. For 1.5 years, the patient has been 
having approximately ten loose stools per day. Apart 
from that, the patient has been exhibiting no other 
symptoms of the disease. The ongoing treatment is 
well tolerated, and the concentrations of hormones, 
neuroendocrine tumour markers and parameters of 
calcium–phosphorus homeostasis are within normal 
ranges. 
Figure 4. Image of the 68Ga-PET/CT scan shows expression of somatostatin receptors in numerous changes of region of aorta in the 
mediastinum (reproduced with permission of L. Królicki, Department of Nuclear Medicine, Medical University, Warsaw)
Rycina 4. Badanie 68Ga-PET/CT uwidaczniające ekspresję receptorów somatostatynowych w licznych zmianach ogniskowych okolicy 
aorty oraz w zmianie ogniskowej zlokalizowanej w śródpiersiu (opublikowane za pozwoleniem L. Królicki, Zakład Medycyny Nuklearnej 
Akademii Medycznej w Warszawie)
Changes in the region of aorta  
(43 × 40 mm — SUV 18.3)  
and new change  
(25 × 24 mm — SUV 12.5)
Change in the mediastinum  
(diameter 15 mm — SUV 22.7)
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Discussion
In principle, each malignant tumour can metastasise to 
the heart. Only tumours of the central nervous system 
have not been proven to develop cardiac metastases. 
The most common neoplasms that metastasise to the 
heart include lung cancer, breast cancer and oesopha-
geal cancer, leukaemia and malignant melanoma [15, 
16]. Tumour cells can metastasise to the heart and peri-
cardium by one of four different pathways: lymphatic, 
haematogenous, direct extension, or intracavitary dif-
fusion through either the inferior vena cava or the pul-
monary veins. Cardiac metastases are usually small and 
multiple. Single metastases are more frequently found 
in the right side of the heart than in the left. Most cases 
are characterised by diffuse bilateral spread. Metastases 
are most frequently located in the pericardium than in 
the myocardium, and most rarely in the endocardium. 
Intracavitary growth of secondary heart tumours is 
very rare [15, 16]. In the overwhelming majority of 
cases, cardiac metastases are diagnosed in patients with 
advanced disease, with the heart being one of many 
organs affected by metastasis. This is because their size 
principally remains clinically silent and the patients 
predominantly manifest general cancer cachexia. As 
a result, cardiac metastases are often found only after 
a patient’s death during a post-mortem examination [15]. 
The clinical symptoms of cardiac metastases, depending 
on their locality and size, may differ to a great extent, 
ranging from a slight shortness of breath and tachycar-
dia to cardiac arrhythmias leading to sudden cardiac 
death, or symptoms of acute tamponade. 
In the case described, the cardiac metastasis of the 
pNET was detected in the course of generalised disease 
in the form of lymph node metastases and local recur-
rence. The metastasis to the wall of the left ventricle 
occurred through lymphatic pathways. However, it was 
a single pathway, which is rarely detected. The patient 
manifested no clinical symptoms of the metastasis in 
the left ventricular wall. Intravital diagnosis of asymp-
tomatic cardiac metastases is not frequent. There are 
no specific laboratory tests for the diagnosis of cardiac 
metastases. Myocardial metastases are known to be 
a possible cause of moderate elevation of cardiac 
troponin [17]. Irregularities detected on physical ex-
amination and by electrocardiography depend on the 
location of the metastases. Physical examination and 
ECG revealed no irregularities in the patient concerned. 
The CT and MR are imaging techniques, with various 
sensitivity depending on the size of metastases and 
their location. The method of choice for the detection 
of cardiac metastases is two-dimensional echocardiog-
raphy [18]. In the patient described, the cardiac lesion 
was first found in the 68Ga-PET/CT scan in January 2010. 
Despite repeated echocardiography tests, it was only 
in September 2012 that an abnormal echocardiogram 
was detected. The great role of somatostatin analogue 
receptor PET imaging in patients with highly differenti-
ated endocrine tumours of the gastrointestinal system 
is well known [4, 11]. It is estimated that the sensitivity, 
specificity and accuracy of the 68Ga-PET/CT scan in these 
patients amount to 97%, 92% and 96% respectively [19]. 
The case of our patient indicates that the enormous 
significance of the 68Ga-PET/CT scan in highly differenti-
ated endocrine tumours of the gastrointestinal system 
is independent of the location of the lesions.
There is no standard treatment for cardiac metasta-
ses. Because, in the overwhelming majority of patients, 
Rycina 5. Image of the 68Ga-PET/CT scan shows expression of somatostatin receptors in numerous changes of region of aorta in the 
mediastinum
Rycina 5. Badanie 68Ga-PET/CT uwidaczniające ekspresję receptorów somatostatynowych w licznych zmianach ogniskowych 
okolicy aorty
Focuses in the region of aorta  
(40 × 33 × 37 mm — SUV 20.6
37 × 34 × 28 mm — SUV 17.2 
36 × 25 × 43 mm — SUV 23.8
Active malignancy in the abdomen. Absent focus in the chest. The possibility infiltration of the gastric wall.
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such metastases are diagnosed in the course of the 
disease with multiple metastases to numerous organs, 
a systemic treatment is used wherever possible. Cardiac 
and circulatory symptoms are alleviated by pharma-
cological methods. Prognosis for these patients is very 
unfavourable and surgical resection is indicated only in 
exceptional cases. Radical resection is often unsuccess-
ful and the post-operative mortality rate is high. In the 
case described, the detected cardiac metastasis was of 
a single type and despite the diagnosis of an advanced 
disease and lack of cardiac symptoms, a decision was 
made to perform a surgical removal of the metastatic 
tumour from the heart. The procedure consisted in 
total removal of the irregular mass from the wall of 
the left ventricle and the subsequent histopathological 
examination confirmed the presence of PNEN tissue. 
The removal of the tumour helped prevent the occur-
rence of cardiac and circulatory symptoms, including 
sudden cardiac death. 
Another treatment method for cardiac metastases is 
radiation therapy. However, this method may lead to 
pulmonary and myocardial fibrosis resulting in distur-
bances of the conduction system and pericarditis. The 
efficacy of radiation therapy depends not only on the 
locality of the lesions but also on the type of tumour 
cells. The recommendations for PNENs treatment do 
not propose radiation therapy [4, 8]. 
 Because the cardiac metastasis was confirmed in 
the course of generalised, progressing disease, systemic 
therapy remains the basic method of treatment. In the 
treatment of both secreting and non-secreting PNENs, 
a significant role is played by somatostatin analogues 
(SSA). The antiproliferative effect of SSA, tending to 
be spectacular in some case studies, was confirmed in 
phase III trials [4, 20]. In the patient described, further 
symptomatic progression was confirmed earlier during 
SSA therapy, which results in a single SSA therapy not 
being the target one. The chemotherapy used earlier 
was not effective either. A new treatment option for 
PNENs is the application of molecularly targeted agents 
[4, 8]. Sunitinib, which is a multi-target receptor kinase 
inhibitor, and everolimus, which is a mammalian target 
of rapamycin inhibitor, are registered for the treatment 
of advanced PNENs, with progression of the disease fol-
lowing chemotherapy [21, 22]. The patient was started 
on sunitinib and continues the SSA therapy. The toler-
ance of the ongoing treatment has been very good; the 
patient suffered no side effects from the administered 
drug. Test results indicate that the metastases have 
been reduced in size and no other sites of the disease 
have been found. 
This report describes a case of a ten-year course of 
the disease, including an eight-year treatment of meta-
static condition. Only one case of a PNEN patient with 
cardiac metastasis has been described to date [14]. In 
contrast to that patient, ours received successful post-
operative treatment due to cardiac metastasis.
Summing up, the application of various methods of 
treatment, not excluding cardiosurgical operations, in 
patients with generalised pancreatic neuroendocrine 
tumour with low proliferative potential, offers patients 
the chance to prolong their survival and maintain 
a good quality of life.
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